Background: Therapeutic radiotherapy is an important treatment of pelvic cancers. Historically, low-fiber diets have been recommended despite a lack of evidence and potentially beneficial mechanisms of fiber.
INTRODUCTION
Radiation therapy is used in $50% of cancer patients and plays a critical role in 25% of cancer cures. It is estimated that in the United States, w300,000 patients/y receive radiotherapy for pelvic or abdominal malignancies (1, 2) . In the United Kingdom, an estimated 17,000 patients/y receive radical (curative) radiotherapy (3) . Despite major advances in radiotherapy techniques, radiation-induced gastrointestinal toxicity is common. Acutely (during treatment), 90% of patients experience changes in bowel habit (4) . Delayed intestinal radiation toxicity is a progressive condition with few therapeutic options and substantial long-term morbidity and mortality (5) . Currently there are an estimated 1.6 million Americans living with postradiation intestinal dysfunction (1) . Modern innovation in radiation technique may reduce the severity of acute and chronic toxicity, but it is unlikely ever to abolish it completely.
Therapeutic strategies for the prevention of radiation-induced gastrointestinal toxicity are limited. The free radical scavenger, amifostine, is the only FDA-approved agent, but concerns remain regarding its side effects and its potentially tumor-protective properties (1) . Dietary strategies have been trialed primarily as prophylactic agents but with limited success (6) , although lack of evidence may be partly explained by the poor quality of many studies and the acknowledged difficulties of undertaking robust, placebo-controlled dietary interventions (7) . Clinical benefit for the manipulation of dietary fiber is inconclusive. Four randomized controlled trials (RCTs) have been conducted recruiting 264 patients in total (8) (9) (10) (11) . Three used fiber supplements in combination with low-fat or low-lactose diets (8, 9, 11) , whereas another used a low-fiber diet in combination with a low-lactose diet (10) , thus limiting the conclusions that could be drawn.
Anecdotal evidence suggests that many patients are advised to reduce fiber intake during pelvic radiotherapy. However, highfiber intake may be beneficial via multiple mechanisms. Fermentable (soluble) fiber provides a substrate for the production of short-chain fatty acids (SCFAs) with beneficial effects on gut health (12) , such as promotion of sodium and associated water uptake and anti-inflammatory activity (13) . The gastrointestinal mucosal response to radiation is proinflammatory (14) with pathological parallels to inflammatory bowel disease (15) , where high-fiber interventions have been shown to be effective (16) .
This RCT was designed to test the hypothesis that a high-fiber diet would prevent or reduce acute and chronic radiation-induced gastrointestinal toxicity in patients undergoing radiotherapy for pelvic cancers. Its secondary objectives were to examine clinical outcomes of importance to patients including quality of life, impact on stool frequency and form (consistency), and nutritional intake.
METHODS
This 2-center, 3-arm (low fiber, habitual fiber, high fiber), RCT (clinicaltrials.gov ID: NCT 01170299) was conducted in compliance with Consolidated Standards of Reporting Trials recommendations (17) . It was approved by the institutional committees for clinical research, and ethical consent was granted by the local Research Ethics Committee.
Patients and radiotherapy protocols
Patients were recruited from the Royal Marsden NHS Foundation Trust, Sutton, Surrey and London and from the Royal Surrey County Hospital, Guildford, Surrey. Eligible patients were those with histologically proven gynecologic or lower gastrointestinal cancer, due to receive radical (curative) radiotherapy to the pelvis, with or without concomitant chemotherapy, and able to tolerate 100% oral diet. Those with established wheat intolerance or celiac disease, a gastrointestinal stent, or a gastrointestinal stoma or enrolled in other trials with conflicting toxicity endpoints were excluded.
Radiotherapy treatment (all pelvic sites) was delivered by using external beam or intensity-modulated radiotherapy techniques (Supplemental Table 1 ). All patients received $45 Gray to the pelvis in 1.8-Gray daily fractions, 5 times/wk, over 5-7 wk. Patients with gynecologic cancers received high-or low-dose adjuvant brachytherapy where indicated. Concomitant chemotherapy comprised oral daily capecitabine and mitomycin C in combination with oral capcitabine and weekly intravenous cisplatin for colorectal, anal, and cervical cancers respectively.
Trial design
Informed, signed consent was obtained before any studyrelated procedures. After collection of baseline data, patients were allocated to a study group with the use of the minimization method by the Institute of Cancer Research Randomization Unit and stratified by pelvic site and receipt of concomitant chemotherapy. The 3 study groups comprised 1) a low-fiber diet [target of #10 g nonstarch polysaccharide (NSP)/d], 2) a habitual or ad libitum diet (control group), and 3) a high-fiber diet (target of $18 g NSP/d). Patients and investigators were unblinded to intervention.
Patients in all study groups received an enrollment (start of treatment) and exit (end of treatment) interview with the study dietitian and a minimum of 2 on-treatment interviews, each of 20-30 min duration during their radiotherapy. Interviews were designed to allow for collection of study outcome measurements and to review compliance with treatment allocation (i.e., fiber targets). At the enrollment interview, patients allocated to the high-or low-fiber groups were given a daily fiber target and counseled on how to achieve this target. The intervention was based entirely on dietary manipulation with fiber supplements neither provided nor recommended. Counseling to achieve the required dietary fiber targets comprised an individualized discussion regarding usual food choices with emphasis on fiber-rich foods and an agreement as to how to adjust these choices to achieve the prescribed target. In addition, patients were given educational and recording items, including a "Fiber in Foods" booklet specifically designed for the trial detailing the fiber content in "points" (or exchanges) of .400 foods commonly consumed in the United Kingdom and an Exchange Diary in which to track their fiber intake to improve understanding, motivation, and compliance. In contrast, patients in the habitualfiber (control) group were counseled at their enrollment interview to maintain their normal diet throughout radiotherapy treatment and not to adjust their fiber intake. However, they still had the same number of study visits and access to the research team, although educational or recording materials were not provided to this group. Patients in all groups had access to the research dietitian throughout the study to answer ad hoc study-related dietary or nutritional queries. The duration of each face-to-face interview during the study was recorded, and the median contact time per interview compared between study groups.
Outcome measurements
Gastrointestinal toxicity was assessed as severity of bowel symptoms experienced during the acute (baseline to 5-7 wk) and chronic (1 y after completion of radiotherapy) period. Symptoms were assessed by using the Inflammatory Bowel Disease Questionnaire-Bowel Subset (IBDQ-B), which has been validated in the radiotherapy setting (4) . The 32-question Inflammatory Bowel Disease Questionnaire (IBDQ) is a qualityof-life instrument originally developed for patients with inflammatory bowel disease (18) . A maximum score of 224 and minimum of 32 can be obtained, with lower scores indicating most severe symptoms. The 10-question (embedded) IBDQ-B has a maximum score of 70 and minimum of 10; once again lower scores indicative of more severe symptoms.
The IBDQ and IBDQ-B scores were obtained at baseline, immediately before commencing radiotherapy, and thereafter weekly during the 5-7 wk of radiotherapy and 1 y after delivery of the last radiotherapy session. The data were analyzed as absolute values for the nadir (worst) score, end of radiotherapy (acute), and 1 y after the final radiotherapy (chronic), as well as the change in values from baseline to each of these time points. Total acute bowel symptom burden, as a predictor of chronic burden (19) , was examined by computing the IBDQ-B AUC in patients with $4 consecutive acute scores. The primary outcome was the difference between study groups in the change in IBDQ-B between the baseline score and the nadir during radiotherapy.
Other gastrointestinal outcomes included stool form (consistency) and frequency (output). Patients were instructed in the completion of daily self-reported stool diaries, which included the Bristol Stool Form Scale (20) for the assessment of stool form, starting on the day after their enrollment interview through to their exit interview, covering their entire radiotherapy treatment period. Mean weekly stool frequency, stool form, the number of days on which stools of type 6/7 were passed, and the number of days on which antidiarrheal medication was used were compared between groups during week 1, week 4, and the final week of radiotherapy.
Stool SCFA concentrations were measured, to investigate the effect of fiber intake on these and to explore whether they may be protective mechanisms in preventing radiation-induced gastrointestinal toxicity. Stool samples were collected from patients on day 1 and the final day of radiotherapy and immediately weighed and stored at 2808C for future analysis of SCFA by using gasliquid chromatography. Briefly, SCFAs were extracted in a 1:4 dilution of extraction buffer (1% dihydrogen phosphate, 0.1% mercuric chloride) containing an internal standard (2,2-dimethylbutyric acid) and homogenized (Seward Stomacher 80). The extraction was centrifuged (Beckman GS6R) at 5000 3 g for 20 min and the supernatant passed through a 0.2-mm filter. In duplicate, filtered supernatant was injected splitless into a gasliquid chromatography system and analyzed by using a chromatogram database (Aligent Technologies) to give concentrations of acetic, propionic, butyric, valeric, isobutyric, and isovaleric acids in micromoles per gram wet stool.
All patients completed a 7-d food diary during their first and last weeks of radiotherapy, prospectively recording all food and fluid consumption. Data were entered into a food composition database (Dietplan v.6; Forestfield Software Ltd.). Fiber intake was recorded as NSP intake per day, and absolute and change values were calculated and compared. Compliance with the fiber target was defined as achieving 80% of the target for that group, equating to ,12.0 g NSP/d for the low-fiber group (target #10 g/d), a change of ,20% in NSP intake between the first and final week for the habitual-fiber group, and .14.4 g NSP/d for the high-fiber group (target $18 g/d). Body weight and BMI (in kg/m 2 ) were obtained at baseline and end the of radiotherapy, and absolute and change values were compared between groups.
Palatability of the intervention diets was assessed at the end of radiotherapy by using a 150-mm visual analog scale with responses ranging from 0 mm ("much worse than my normal diet") to 75 mm ("no different to my normal diet") and 150 mm ("much better than my normal diet"). The impact of following the intervention diets on the cost of weekly food bills and time spent shopping and in food preparation was assessed by the study research dietitian at the exit interview and is reported descriptively. Participants were also asked at each study visit to recall any costs they had incurred that were directly related to symptom management (e.g., purchase of incontinence pads).
Statistical methods
Statistical analysis was performed by using SPSS software (v.21) using the ANOVA method for normally distributed data (e.g., IBDQ-B and total IBDQ scores) or the Kruskal Wallis test for nonnormally distributed data (e.g., stool frequency) between the 3 groups. Where significant, intergroup comparisons were compared by using a Bonferroni post hoc correction. The primary endpoint was defined as the change in IBDQ-B score between the start of radiotherapy and the nadir during the radiotherapy period (acute). This was analyzed by intention-to-treat (ITT) and per protocol methods. For ITT analysis, missing baseline scores were imputed by carrying backward the first available score, and missing scores at the end of radiotherapy or 1 y were imputed by using last value carried forward. Missing scores during treatment were imputed by taking an average of scores on either side of those missing. Data from patients who withdrew from the trial before commencing the intervention were excluded from the analysis. Data from patients who withdrew during the intervention but consented to allow their data to be included were included in the ITT analysis. Per-protocol analysis was performed by using scores from patients who achieved $80% compliance with fiber target, assessed from the 7-d food diary for the last week of treatment. Results of these analyses were considered significant if P , 0.05 (ANOVA), in which case post hoc analysis was undertaken.
The sample size calculation was based on a previous nutrition intervention study with a similar design using the IBDQ-B score as the primary endpoint (21) . It was calculated that 156 patients were required (52 patients/group) to detect a difference in a change of $6 points in the IBDQ-B score between groups from the start of radiotherapy to the nadir during treatment, with a significance level of 0.02 (allowing for multiple comparisons) and power of 90%. Values are expressed as means 6 SDs.
RESULTS

Patients
Recruitment took place between December 2009 and December 2013 and was closed when accrual reached n = 166, with 10 additional patients recruited to allow for withdrawals. The final trial measurement (1-y follow-up) was obtained in January 2015. Figure 1 outlines study accrual. Of the 583 eligible patients, 417 declined, representing a recruitment rate of 28%. The major reason for declining study enrollment was reluctance to adopt a possible change in diet (36% of patients).
Seven patients withdrew: 2 declined to commence the study immediately after random assignment (low-fiber group), 2 had a stoma placed before radiotherapy (habitual fiber: 1, high fiber: 1); 2 were hospitalized during treatment and requested withdrawal (habitual fiber: 1, low fiber: 1), and 1 had a change in treatment plan and did not receive radiotherapy (high fiber). A total of 161 patients comprised the ITT population as follows: 159 completed the intervention, and 2 withdrew partly through the study but consented to their data being included. Four adverse events occurred, all of which were hospital admission for symptom control. None of these was considered related in any way to the study intervention. There were no significant differences in baseline characteristics between groups ( Table 1) .
A total of 644 face-to-face interviews with patients were conducted by the study dietitian. The median contact time per interview was not significantly different between groups (P = 0.161) and amounted to 16 min for the habitual-fiber group (minimum: 11 min, maximum: 36 min), 18 min (minimum: 9 min, maximum: 31 min) for the low-fiber group, and 18 min (minimum: 10 min, maximum: 34 min) for the highfiber group.
IBDQ-B
IBDQ-B scores were obtained weekly for all patients. The number of missing scores, requiring imputation, for weeks 1-6 and 1 y postradiotherapy was 1, 5, 7, 10, 17, 9, and 35, respectively. Raw scores and comparisons between groups at all time points are shown in Table 2 . There were no differences in IBDQ-B scores at baseline between the 3 groups. Overall, IBDQ-B scores decreased in all groups during treatment, indicative of worsening bowel symptoms. In the ITT population, there was no significant difference between groups in the change between the baseline score (start of radiotherapy) and the nadir during treatment (primary endpoint, P = 0.093).
There were no differences in absolute IBDQ-B scores at the end of radiotherapy between the 3 groups; however, there was a significant difference in the between-group change in scores between baseline and final week of radiotherapy (P = 0.014) ( Table 2 ). Post hoc analysis revealed a smaller reduction in score in the high-fiber group (23.7 6 12.8) compared with the habitual-fiber group (210.8 6 13.5), a clinically significant difference of 27.1 points (95% CI: 212.99, 21.27; P = 0.011). However, the change in score was not significantly different between the low-fiber group (27.9 6 11.3) and the habitualfiber group (P = 0.711) or between the low-fiber and high-fiber groups (P = 0.251). The absolute IBDQ-B scores at 1 y postradiotherapy and the change in scores between baseline and 1 y postradiotherapy were significantly different between groups ( Table 2) . Post hoc analysis revealed that at 1 y after radiotherapy, IBDQ-B scores had returned to baseline values in the high-fiber group (+0.1 6 14.5) compared with a reduction in the habitual-fiber group (28.4 6 13.3), a clinically significant difference of 28.5 points (95% CI: 214.8, 22.2; P = 0.004). However, the change in IBDQ-B scores was not significantly different between the low-fiber group (24.9, SD 12.7) and the habitual-fiber group (P = 0.546) or between the low-fiber and high-fiber groups (P = 0.172) ( Table 2) .
Per protocol analysis revealed no significance differences between groups in IBDQ-B scores at any time points or in the change in scores between time points. However, patient numbers were small, with only 128 patients (n = 34 for low fiber, n = 22 for habitual fiber, and n = 27 for high fiber) included in the analysis because of limited numbers achieving $80% compliance with the fiber target.
Computation of IBDQ-B AUC (153 patients) showed no significant difference between groups (P = 0.576; Kruskal Wallis test, nonparametric data).
IBDQ
IBDQ scores were obtained weekly for all patients with missing scores imputed as reported above for IBDQ-B. Raw scores and comparisons between groups at all time points are shown in Table 2 . There were no differences in IBDQ scores at baseline between the 3 groups. Overall, scores decreased in all groups during treatment, indicative of worsening overall symptoms and resulting impaired quality of life. In the ITT population, there was no significant difference between groups in the change in score between baseline (start of radiotherapy) and the nadir during treatment (P = 0.203).
There was no difference in absolute IBDQ scores at the end of radiotherapy between the 3 groups; however, there was a significant difference in the change in score between baseline and the final week of radiotherapy (P = 0.018). Post hoc analysis revealed a smaller reduction in score in the high-fiber group (28.2 6 30.2) compared with the habitual-fiber group (224.5 6 32.0), a clinically significant difference of 216.2 points (95% CI: 230.12, 22.46) (P = 0.015). However, the change in score was not significantly different between the low-fiber and habitual-fiber groups (P = 0.708) nor between the low-fiber and high-fiber groups (P = 0.303).
The absolute IBDQ scores at 1 y postradiotherapy (P = 0.001) and the change in scores between baseline and 1 y after radiotherapy were significantly different between groups (P , 0.001). Post hoc analysis revealed that at 1 y after radiotherapy, IBDQ scores had returned to exceed baseline values marginally in the high-fiber group (+2.1 6 29.4) compared with a reduction in the habitual-fiber group (221.4 6 33.0), a difference of 223.8 points (95% CI: 238.2, 29.3) (P , 0.001). The change in IBDQ scores was also significantly different between the low-(213.23 6 30.3) and high-fiber groups (P = 0.030) but not between the low-fiber and habitual-fiber groups (P = 0.530) ( Table 2) .
Per protocol analysis (n = 34 for low fiber, n = 22 for habitual fiber, n = 27 for high fiber) revealed a significant difference between groups in IBDQ scores at 1 y after radiotherapy (P = 0.030). Post hoc analysis revealed a significant difference of 20.4 points (95% CI: 1.9, 38.9) (P = 0.026) between the highfiber and habitual-fiber groups. However, there were no differences between groups in the change in IBDQ score between any time points.
Stool frequency and form
Stool diaries were returned by 125 (78%) patients, (39/53 in the low-fiber group; 44/54 in the habitual-fiber group; 42/54 in the highfiber group). There were no significant differences in stool frequency or stool form during week 1 (start of radiotherapy) or the final week (end of radiotherapy) between any of the 3 groups, nor was there a difference in the number of days during which patients experienced a stool form of 6 or 7 (loose or watery stools) or the number of days on which antidiarrheal medication was taken ( Table 3) .
SCFAs
In an exploratory analysis, paired stool samples were provided by a subgroup of 41 patients at baseline and at the end of radiotherapy (low-fiber group: 15, habitual-fiber group: 16, and high-fiber group: 10). No significant differences were found between groups in total SCFA concentrations either at baseline or the end of radiotherapy (Supplemental Table 2 ).
Nutritional data
The number of 7-d food diaries returned was 146 (91%) at baseline (47 in the low-fiber group, 51 in the habitual-fiber group, and 48 in the high-fiber group) and 139 (86%) during the final week of radiotherapy (41 in the low-fiber group, 44 in the habitual-fiber group, and 43 in the high-fiber group). During week 1 of radiotherapy, after dietary advice, there was a significant difference in fiber intake between groups (P , 0.001: ANOVA), which was also apparent during the final week of radiotherapy (P , 0.001: ANOVA), all in line with group allocations (low Week 1 (start of radiotherapy) 3 (0-7) 2 (0-7) 2 (0-7) 0.627 Final week (end of radiotherapy)
3.0 (0-7) 3.0 (0-7) 3.0 (0-7) 0.934 Antidiarrheal medication used, d/wk
Week 1 (start of radiotherapy) 0 (0-7) 0 (0-7) 0 (0-2) 0.713 Final week (end of radiotherapy) 0 (0-7) 0 (0-7) 0 (0-7) 0.515 1 Values are medians (minimums-maximums). 2 Kruskal-Wallis test.
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fiber , habitual fiber , high fiber) ( Table 4 ). There were no differences between groups in the intake of fat or carbohydrates during week 1 and the final week of radiotherapy or change between week 1 and the final week. However, there was a significant difference in protein intake between groups (P = 0.012) during the final week of radiotherapy (Table 4 ). Post hoc analysis revealed a mean difference of 14.6 g protein/d between the low-and highfiber groups (68.6 6 24.5 compared with 78.4 6 22.7, P = 0.011). By using paired data (food diaries returned at both time points) significant within-group reductions in the low-and habitual-fiber groups were seen in total energy (low fiber: 2146 kcal/d, habitual fiber: 2171 kcal/d; P = 0.019 and 0.010, respectively), protein (low fiber: 28.5 g/d, habitual fiber: 27.7 g/d; P = 0.002 and 0.006, respectively), and fat (low fiber: 27.5 g/d, habitual fiber: 28.3 g/d; P = 0.014 and 0.016, respectively) intake between week 1 and the final week of radiotherapy. In contrast, no significant differences in nutrient intake were observed in the high fiber group.
There were no significant differences in body weight or BMI at either baseline or the end of radiotherapy (Table 4 ). Difference in the change in BMI between groups was significant. Post hoc analysis revealed this to be between the low-and habitual-fiber groups (P = 0.058).
Of the 40 of 53 (75%) patients in the low-fiber group and 38 of 54 (70%) in the high-fiber group who completed the palatability questionnaires, there was no significant difference in perceived palatability of the low-fiber diet [median: 78.5 mm (minimum: 7 mm, maximum: 146)] compared with the high-fiber diet [median: 78.0 mm (minimum: 5 mm, maximum: 150 mm)]. There was little difference between the high-and low-fiber groups with respect to the impact of the study diet. A total of 64% of patients in the low-fiber group compared with 59% in the high-fiber group reported that the study diet had a minimal effect or had reduced the cost of their weekly food bills; 60% of patients in the low-fiber group compared with 58% in the high-fiber group reported that the study diet had no impact or reduced time spent shopping, and 64% of patients in the low-fiber group compared with 56% in the high-fiber group reported that the study diet had no effect or had reduced food preparation time. There was no response from 27% of patients in the low-fiber group and from 34% of patients in the high-fiber group.
Widespread inability among trial participants to recall specific costs associated with symptom management precluded formal analysis.
DISCUSSION
This is the first RCT designed to test the efficacy of manipulating dietary fiber in patients receiving radical pelvic radiotherapy. Although no significant difference between groups was found in the primary outcome (change in IBDQ-B between the baseline and the nadir), the results revealed a clinically significant difference in the change in score of 7.1 points (P = 0.011) between the high-fiber and habitual-fiber groups, between the start and the end of radiotherapy, pointing to a clear benefit of increased fiber intake. The fact that at 1 y postradiotherapy the difference in score between these groups was 8.5 points (P = 0.004), indicating a longer-term effect, fits with the current concepts of radiotherapy toxicity that encompass the consequential effect (22) , namely that severe acute toxicity predisposes to longer-term severe toxicity. These differences between groups in the change in IBDQ-B score are equivalent to a $10% change, which has previously been defined as "meaningful clinical improvement" (23) . It should be noted that despite these results we did not show a gradient of effect. IBDQ-B scores in the low-fiber group were higher (less severe symptoms) at both time points compared with the habitual-fiber group, albeit not statistically significantly, indicating a possible benefit. The analysis of IBDQ (quality-of-life) scores revealed a similar pattern, with the highfiber group maintaining significantly improved scores compared with the habitual-fiber group at the end of radiotherapy (P = 0.015) and at 1 y (P # 0.001).
Conducting robust, large-scale nutritional interventions requiring patients to adhere to targets and estimate intake is laborintensive and far from straightforward. We set fiber targets based on the NSP content of foods to ensure compatibility with Dietary Reference Values in the United Kingdom at the time (24) and provided a study-specific booklet for patients to readily track their intake. Patients were coached to use this booklet rather than food labels as their prime reference source and were given diaries in which to record daily self-estimated fiber consumption. In the United Kingdom, food labeling is based on the US Association of Official Analytic Chemists method of analysis, which yields values 1.6 3 NSP/100 g food. Despite these potential pitfalls, we are confident in the validity of our findings because a clear differential in fiber intake was maintained between groups during the first and final week of treatment (P , 0.001 both time points). Most patients (85%) reported they found the booklets very easy to use and would recommend them to others wishing to track their fiber intake. We conclude from these results that patients in this setting can meet targets for fiber intake for the duration of their treatment period by using dietary manipulation alone. Although, we acknowledge that the achievement of compliance is a potentially complex process, for researchers and patients alike.
Importantly, our findings challenge non-evidence-based advice to restrict dietary fiber during radical pelvic radiotherapy. Analysis of stool frequency and form and the number of days on which loose or watery stools were experienced showed no significant differences between groups in any of these characteristics. Thus, the premise that increased fiber exacerbates a tendency toward treatment-induced diarrhea appears to lack physiologic foundation. On the contrary, optimal production of SCFA by bowel microbiota provided with ample fiber substrate would encourage sodium and water absorption (12) and thus help counteract the risk of loose or watery stool. In addition to promoting water absorption, we hypothesized that increased fiber intake would enhance SCFA production, which in turn would reduce inflammatory processes, thereby mitigating symptoms as reflected in the IBDQ-B scores. However, we found no difference between groups. This may be because of the small number of samples we obtained, the wide interindividual variations in stool SCFA concentrations that exist (25) , and altered gut transit time during treatment (26, 27) , which has a large effect on stool SCFA concentrations. Further studies are needed to explore our hypothesis.
Our interventions had no adverse effect on body weight or total energy intake. The difference between the low-and habitual-fiber groups in the change in BMI was of only borderline significance. Although all of these variables decreased in all groups between baseline and the end of radiotherapy, no significant differences between groups occurred. Within-group analysis revealed no significant change in total energy or macronutrient intake in the high-fiber group, a finding in keeping with recent research, which challenges the long-held view that fiber leads to increased satiety and causes reduced energy intake (28, 29) . However, significant within-group reductions in protein, fat, and total energy intake occurred in the habitual-and low-fiber groups between baseline and the end of radiotherapy. We cannot determine whether maintenance of total energy intake in the high-fiber group contributed to their improved quality-of-life (IBDQ) scores or vice versa, although others have reported an association (30, 31) .
We recognize that there are a number of factors that could have confounded our results. First, there was considerable attrition at 1 y, requiring imputation for ITT analysis. However, the habitualfiber group who reported the worst bowel symptoms in the acute setting also went on to experience the worst symptoms at 1 y postradiotherapy, which fits with previous research (5, 22) . Second, treatment-related factors were balanced between groups at baseline. However, patient-related factors, such as smoking history, inflammatory conditions, and previous surgery, all of which confer an adverse effect and in contrast, the use of antihypertensive medication and/or 3-hydroxy-3-methyl-glutarylcoenzyme A reductase inhibitors, which confer a protective effect (32) and could have influenced outcomes, were not captured. Third, cytotoxic agents (antimetabolite capecitabine and alkylating agents mitomycin C and cisplatin) and/or noncancer-related medications, may cause gastrointestinal symptoms in their own right through inflammatory or other mechanisms and thus may exacerbate symptoms and overwhelm potentially protective nutritional agents.
We conclude that individualized dietetic advice to follow a highfiber diet during pelvic radiotherapy was tolerable and resulted in reduced gastrointestinal toxicity both acutely at the end of radiotherapy and at 1 y after radiotherapy compared with habitual-fiber intake. Because we used a physiologic (dietary) intervention, we are not able to determine whether any specific component or type of fiber confers most benefit (e.g., readily versus poorly fermentable) because all foods contain a diverse range of fiber substrates. We note that a low-fiber diet also appeared to confer some benefit and may offer a degree of advantage via different mechanisms. However, we agree with others in that a critical objective for dietetic practice is that ineffective, unnecessary, or restrictive practices that lack an evidence base and yet place undue burden on patients are abandoned (31) , and thus our recommendation is that advice to reduce fiber intake during pelvic radiotherapy be discarded.
